Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9988
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. Its lead product, Xtampza ER is designed to provide adequate pain control. Collegium’s other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta for the management of acute pain severe enough to require an opioid analgesic. Collegium is headquartered in Canton, Massachusetts, the US.

Collegium Pharmaceutical Inc (COLL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Collegium Pharma Raises USD50 Million in Venture Financing 13
Collegium Pharma Raises US$4 Million In Venture Financing 15
Collegium Pharma Raises US$22.5 Million In Series B Financing 16
Licensing Agreements 17
Collegium Pharma Enters into Licensing Agreement with Depomed 17
Equity Offering 18
Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18
Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19
Collegium Pharma Raises USD55 Million in Public Offering of Shares 21
Collegium Pharma Raises USD80 Million in IPO 23
Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25
Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26
Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27
Collegium Pharmaceutical Inc – Key Competitors 28
Collegium Pharmaceutical Inc – Key Employees 29
Collegium Pharmaceutical Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 08, 2018: Collegium reports second quarter financial results and provides corporate update 31
May 09, 2018: Collegium Reports First Quarter Financial Results and Provides Corporate Update 2018 33
Mar 07, 2018: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 2017 35
Nov 08, 2017: Collegium Announcers Third Quarter Financial Results and Provides Corporate Update 37
Aug 09, 2017: Collegium Reports Second Quarter Financial Results and Provides Corporate Update 39
May 10, 2017: Collegium Reports 2017 First Quarter Financial Results and Provides Corporate Update 41
Mar 09, 2017: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 42
Corporate Communications 43
Jul 10, 2018: Collegium Promotes Scott Dreyer To CCO 43
Jun 04, 2018: Collegium Promotes Joseph Ciaffoni To Chief Executive Officer 44
May 30, 2017: Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer 45
Product News 46
06/08/2017: Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids 46
06/01/2017: Collegium Announces Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients 47
04/03/2017: Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients 48
02/01/2017: Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER 49
Clinical Trials 50
Mar 16, 2017: Collegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Collegium Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Collegium Pharma Raises USD50 Million in Venture Financing 13
Collegium Pharma Raises US$4 Million In Venture Financing 15
Collegium Pharma Raises US$22.5 Million In Series B Financing 16
Collegium Pharma Enters into Licensing Agreement with Depomed 17
Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18
Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19
Collegium Pharma Raises USD55 Million in Public Offering of Shares 21
Collegium Pharma Raises USD80 Million in IPO 23
Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25
Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26
Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27
Collegium Pharmaceutical Inc, Key Competitors 28
Collegium Pharmaceutical Inc, Key Employees 29
Collegium Pharmaceutical Inc, Subsidiaries 30

List of Figures
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SOLX Inc-医療機器分野:企業M&A・提携分析
    Summary Solx Inc (SOLX) is a medical device company that develops therapeutic products. The company provides glaucoma surgery devices and treatments for glaucoma therapy. Its SOLX gold shunt is a minimally invasive device, which is used in surgical treatment of glaucoma. SOLX’s product is a gold imp …
  • Kyochon F&B Co., Ltd.
    Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Newrest Group International S.A.S:企業の戦略・SWOT・財務情報
    Newrest Group International S.A.S - Strategy, SWOT and Corporate Finance Report Summary Newrest Group International S.A.S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Nomura Research Institute Ltd (4307):企業の財務・戦略的SWOT分析
    Nomura Research Institute Ltd (4307) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • CymaBay Therapeutics Inc (CBAY):企業の財務・戦略的SWOT分析
    CymaBay Therapeutics Inc (CBAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • K&H Bank Zrt:企業の戦略・SWOT・財務情報
    K&H Bank Zrt - Strategy, SWOT and Corporate Finance Report Summary K&H Bank Zrt - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Duopharma Biotech Berhad (DPHARMA):企業の財務・戦略的SWOT分析
    Summary Duopharma Biotech Berhad (Duopharma), formerly CCM Duopharma Biotech Berhad, focuses on research, development and commercialization of generic drugs and biosimilars. The company manufactures and distributes pharmaceutical products to treat oncology and diabetes; musculo-skeletal, alimentary …
  • Lululemon Athletica, Inc. (LULU):企業の財務・戦略的SWOT分析
    Lululemon Athletica, Inc. (LULU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Intersect ENT Inc (XENT):企業の財務・戦略的SWOT分析
    Summary Intersect ENT Inc (Intersect), formerly Sinexus Inc is a medical device company that offers chronic sinusitis solutions. The company offers steroid releasing implants and mini steroid implants. It provides surgical solutions for patients, disease recurrence with recurrent symptoms. Intersect …
  • Bastide Le Confort Medical SA (BLC)-医療機器分野:企業M&A・提携分析
    Summary Bastide Le Confort Medical SA (Bastide Le) is a medical equipment company that provides personal care products. The company offers medical devices for individuals and home health care professionals. It provides products such as lift chairs and accessories, pillows, cushions and special seati …
  • Mettler-Toledo International Inc (MTD):企業の財務・戦略的SWOT分析
    Mettler-Toledo International Inc (MTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • NRG Energy Inc (NRG)-エネルギー分野:企業M&A・提携分析
    Summary NRG Energy, Inc. (NRG) is an integrated energy company that produces, sells and delivers energy, and energy products and services. The company generates power using diverse sources such as coal, natural gas, nuclear, oil, wind and solar. It trades wholesale energy, capacity, fuel and related …
  • Kangwon Land Inc.:企業の戦略・SWOT・財務情報
    Kangwon Land Inc. - Strategy, SWOT and Corporate Finance Report Summary Kangwon Land Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Waste Management Inc (WM):企業の財務・戦略的SWOT分析
    Waste Management Inc (WM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Emera Inc:発電所・企業SWOT分析
    Emera Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executiv …
  • Mitsubishi Logistics Corporation (9301):企業の財務・戦略的SWOT分析
    Mitsubishi Logistics Corporation (9301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Evotec AG (EVT):医療機器:M&Aディール及び事業提携情報
    Summary Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory dise …
  • Guerbet SA (GBT):医療機器:M&Aディール及び事業提携情報
    Summary Guerbet SA (Guerbet) operates in the contrast-agent field. The company provides a wide range of pharmaceutical products, medical equipments and services for interventional imaging and diagnostic, to improve the diagnosis and treatment of patients. Its major products include diagnostic imagin …
  • Whirlpool Corporation (WHR):企業の財務・戦略的SWOT分析
    Whirlpool Corporation (WHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Consumers Energy Co (CMS PR B):企業の財務・戦略的SWOT分析
    Consumers Energy Co (CMS PR B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆